ChromaDex Corporation - CDXC STOCK NEWS

ChromaDex Corp. (NASDAQ:CDXC) reported third quarter 2021 net sales of $17.3 million, a 22% increase year-over-year. Notably, Tru Niagen® sales reached $14.8 million, up 24%. Despite improved gross margin at 61.1%, the company incurred a net loss of $(8.9) million, deteriorating from $(4.2) million last year. Operating expenses rose to $19.4 million, due in part to increased legal costs. Looking ahead, ChromaDex anticipates continued revenue growth driven by its e-commerce strategy and strategic partnerships, while investing in brand awareness and R&D.

ChromaDex announced promising results from a clinical study on nicotinamide riboside (NR) for patients with ataxia-telangiectasia (AT), a rare neurodegenerative disorder. Conducted by Radboud University Medical Center, the study demonstrated that NR improved ataxia scores and increased immunoglobulin levels in 24 participants, including 17 children. Patients received 25mg/kg of NR daily for four months. Though results are encouraging, further research is needed to confirm the therapeutic potential of NR for AT.

ChromaDex Corp. (NASDAQ:CDXC) will hold a conference call on November 3, 2021, at 4:30 p.m. ET to discuss its third quarter financial results for the period ending September 30, 2021. The results will be disclosed in a press release after market close on the same day. Interested participants should call in 10 minutes prior to the call, with details provided. A replay will be available from 7:30 p.m. ET on November 3 until 11:59 p.m. ET on November 10. ChromaDex focuses on healthy aging, pioneering research around NAD+ and its products.

A jury in the United States District Court for the Central District of California ruled that Elysium Health breached its contract with ChromaDex, leading to damages of $2.25 to $2.50 million plus interest. This decision holds Elysium accountable for unpaid product orders from 2016. ChromaDex aims to leverage this outcome to expand its global growth, partnering with Sinopharm Xingsha, Walmart, and others. The company boasts a strong patent portfolio and successful trials for its flagship product, Niagen®, demonstrating its commitment to healthy aging.

ChromaDex Corp. (NASDAQ: CDXC) has formed a partnership with Sinopharm Xingsha Pharmaceuticals to facilitate cross-border sales of its product, Tru Niagen®, in mainland China. Sinopharm Xingsha is a key subsidiary of Sinopharm Group, involved in drug and health supplement distribution. With a projected 45.2% of China’s population over 50 by 2040, the demand for Tru Niagen® is expected to rise significantly. The collaboration also aims to obtain Health Food Registration in China, enhancing market accessibility for Tru Niagen®, a top NAD⁺ booster.

ChromaDex Corp. (NASDAQ:CDXC) announced significant preclinical findings from its External Research Program focusing on nicotinamide riboside (NR). Studies indicate NR's protective effects on retinal ganglion cells in glaucoma, improvement in Alzheimer’s disease models through enhanced brain NAD+ levels, and cardioprotective benefits in ischemia-reperfusion injury models. Additionally, ChromaDex is supporting clinical trials investigating NR's impact on neurological symptoms in ataxia-telangiectasia and skeletal muscle metabolism. These advancements highlight NR’s potential in addressing age-related conditions.

ChromaDex (NASDAQ:CDXC) announced plans to appeal a September 14 ruling in its patent infringement lawsuit against Elysium Health in the District Court of Delaware. The company holds exclusive rights to nicotinamide riboside (NR) through U.S. Patents 8,383,086 and 8,197,807. Additionally, ChromaDex's product Niagen® is supported by 13 clinical trials and approved by major regulatory bodies including the U.S. FDA and Health Canada. Another lawsuit against Elysium is set for trial on September 21 in California.

ChromaDex Corp. (NASDAQ:CDXC) reported Q2 2021 financial results showing net sales of $17.7 million, a 16% increase year-over-year. Tru Niagen® sales reached $15.4 million, up 31%. The gross margin improved to 61.1%, reflecting effective cost control. However, the company recorded a net loss of $(5.6) million or $(0.08) per share, compared to a loss of $(3.7) million last year. Adjusted EBITDA was $0.6 million, a slight improvement. The company anticipates continued revenue growth and is investing in R&D and marketing.

ChromaDex Corp. (NASDAQ:CDXC) will hold a conference call on August 3, 2021, at 4:30 p.m. ET to discuss its Q2 financial results ending June 30, 2021. The financial results will be released after the market closes on the same day. Interested participants should join 10 minutes early. The call will also provide a general business update. A replay will be available after the call. ChromaDex specializes in healthy aging and is known for its NAD+ precursor, nicotinamide riboside (Niagen®), featured in its Tru Niagen® product.